Roles of AKR1C3 in malignancy

被引：6

作者：

Xiao, Xin-Zhu ^{[1
]}

Lin, Li-Ying ^{[1
]}

Zhuang, Ming-Kai ^{[1
]}

Zhong, Can-Mei ^{[1
]}

Chen, Feng-Lin ^{[1
]}

机构：

[1] Fujian Med Univ, Union Hosp, Dept Gastroenterol, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2021年 / 134卷 / 09期

关键词：

PROSTATE-CANCER; GROWTH;

D O I：

10.1097/CM9.0000000000001379

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1052 / 1054

页数：3

共 50 条

[31] DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling
Gu, Yanan
Wu, Shiqi
Chong, Yue
Guan, Bing
Li, Lei
He, Dalin
Wang, Xinyang
Wang, Bin
Wu, Kaijie
CELLULAR SIGNALLING, 2022, 95
[32] AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK
Wang, Bin
Gu, Yanan
Hui, Ke
Huang, Jun
Xu, Shan
Wu, Shiqi
Li, Lei
Fan, Jinhai
Wang, Xinyang
Hsieh, Jer-Tsong
He, Dalin
Wu, Kaijie
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (10) : 472.e11 - 472.e20
[33] AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p
Pan, Di
Yang, Wanwan
Zeng, Yao
Li, Wenjun
Wang, Kaizhen
Zhao, Li
Li, Jia
Ye, Yuting
Guo, Qinglong
CELLULAR SIGNALLING, 2021, 84
[34] Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism
Sekine, Yoshitaka
Nakayama, Hiroshi
Miyazawa, Yoshiyuki
Kato, Haruo
Furuya, Yosuke
Arai, Seiji
Koike, Hidekazu
Matsui, Hiroshi
Shibata, Yasuhiro
Ito, Kazuto
Suzuki, Kazuhiro
ONCOLOGY LETTERS, 2018, 15 (03) : 3167 - 3172
[35] Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid
Pippione, Agnese Chiara
Carnovale, Irene Maria
Bonanni, Davide
Sini, Marcella
Goyal, Parveen
Marini, Elisabetta
Pors, Klaus
Adinolfi, Salvatore
Zonari, Daniele
Festuccia, Claudio
Wahlgren, Weixiao Yuan
Friemann, Rosmarie
Bagnati, Renzo
Boschi, Donatella
Oliaro-Bosso, Simonetta
Lolli, Marco Lucio
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 150 : 930 - 945
[36] Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
Zhu, Sha
Ni, Yuchao
Wang, Zilin
Zhang, Xingming
Zhang, Yaowen
Zhao, Fengnian
Dai, Jindong
Wang, Zhipeng
Zhu, Xudong
Chen, Junru
Zhao, Jinge
Zeng, Yuhao
Chen, Ni
Zeng, Peng
Shen, Pengfei
Sun, Guangxi
Zeng, Hao
ONCOLOGIST, 2022, 27 (11) : E870 - E877
[37] Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2α
Jeng, Kuo-Shyang
Cheng, Po-Yu
Lin, Yueh-Hsien
Liu, Po-Chun
Tseng, Ping-Hui
Wang, Yu-Chao
Chang, Chiung-Fang
Leu, Chuen-Miin
ONCOLOGY RESEARCH, 2024, 32 (01) : 163 - 174
[38] Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment
Novotna, Eva
Bukum, Neslihan
Hofman, Jakub
Flaxova, Michaela
Kouklikova, Etela
Louvarova, Dagmar
Wsol, Vladimir
BIOCHEMICAL PHARMACOLOGY, 2018, 156 : 22 - 31
[39] Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Verma, Kshitij
Zang, Tianzhu
Penning, Trevor M.
Trippier, Paul C.
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (07) : 3590 - 3616
[40] Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer
Taskoparan, Betul
Seza, Esin Gulce
Demirkol, Secil
Tuncer, Sinem
Stefek, Milan
Gure, Ali Osmay
Banerjee, Sreeparna
CELLULAR ONCOLOGY, 2017, 40 (06) : 563 - 578

← 1 2 3 4 5 →